Eculizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01257 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | cyclic hematopoiesis | KG + DL |
| 2 | autosomal recessive severe congenital neutropenia due to JAGN1 deficiency | KG + DL |
| 3 | X-linked severe congenital neutropenia | KG + DL |
| 4 | congenital neutropenia-myelofibrosis-nephromegaly syndrome | KG + DL |
| 5 | adult idiopathic neutropenia | KG + DL |
| 6 | autosomal recessive severe congenital neutropenia due to CXCR2 deficiency | KG + DL |
| 7 | primary immunodeficiency syndrome due to p14 deficiency | KG + DL |
| 8 | autosomal recessive severe congenital neutropenia due to CSF3R deficiency | KG + DL |
| 9 | severe congenital neutropenia | KG + DL |
| 10 | primary release disorder of platelets | KG + DL |
| 11 | pseudo-von Willebrand disease | KG + DL |
| 12 | Barth syndrome | KG + DL |
| 13 | Glanzmann thrombasthenia | KG + DL |
| 14 | mixed-type autoimmune hemolytic anemia | KG + DL |
| 15 | drug-induced autoimmune hemolytic anemia | KG + DL |
| 16 | constitutional neutropenia | KG + DL |
| 17 | primary CD59 deficiency | KG + DL |
| 18 | cold agglutinin disease | KG + DL |
| 19 | neonatal autoimmune hemolytic anemia | KG + DL |
| 20 | autosomal recessive severe congenital neutropenia due to G6PC3 deficiency | KG + DL |
| 21 | proteinuria | KG + DL |
| 22 | hepatic veno-occlusive disease-immunodeficiency syndrome | KG + DL |
| 23 | hepatic veno-occlusive disease | KG + DL |
| 24 | hepatic infarction | KG + DL |
| 25 | peliosis hepatis | KG + DL |
| 26 | combined immunodeficiency due to CRAC channel dysfunction | KG + DL |
| 27 | pancytopenia due to IKZF1 mutations | KG + DL |
| 28 | Kostmann syndrome | KG + DL |
| 29 | syndrome with combined immunodeficiency | KG + DL |
| 30 | facial dysmorphism-immunodeficiency-livedo-short stature syndrome | KG + DL |
| 31 | absent thumb-short stature-immunodeficiency syndrome | KG + DL |
| 32 | autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis | KG + DL |
| 33 | primary immunodeficiency due to a defect in adaptive immunity | KG + DL |
| 34 | immuno-osseous dysplasia | KG + DL |
| 35 | X-linked lymphoproliferative disease due to SH2D1A deficiency | KG + DL |
| 36 | middle ear neuroendocrine tumor | KG + DL |
| 37 | Scott syndrome | KG + DL |
| 38 | TAFRO syndrome | KG + DL |
| 39 | human herpesvirus 8-related tumor | KG + DL |
| 40 | primary hyperoxaluria | KG + DL |
| 41 | malignant cutaneous granular cell skin tumor | KG + DL |
| 42 | ectomesenchymoma | KG + DL |
| 43 | A20 haploinsufficiency | KG + DL |
| 44 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
| 45 | immune dysregulation with inflammatory bowel disease | KG + DL |
| 46 | hypophosphatasia | KG + DL |
| 47 | Steel syndrome | KG + DL |
| 48 | neutropenia | KG + DL |
| 49 | bleeding diathesis due to a collagen receptor defect | KG + DL |
| 50 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.